Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2268)	2/1/2018 1:47:37 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

Many times I mentioned that REGN MC is very sensitive to Eylea sale performance during current as well next periods (2 years period at least). Main reason that MC reacted negatively to Roche bi-specific news/development. Lucentis significantly underperformed on US 4Q sale (288M CHF, $309M, -28% from 3Q), while Eylea did $974M v 953M, +2.2%. Going into 2018, Eylea continue to dominate market with +10% growth, ...With this dynamic, better they do something about future.